Australia's CSL tanks to nearly 7-year low on spin-off delay, outlook downgrade

Csl

28/10/2025 03:55

Updates

** CSL CSL.AX tanks as much as 16.8% to A$176.01, lowest since December 24, 2018

** Stock logs steepest intraday pct drop since mid August

** Biotech giant no longer expects to complete divestment of its vaccine division in FY26

** Cites heightened volatility in U.S. influenza vaccine market

** Says demerger now expected to occur when market conditions support maximizing shareholder value

** Cuts FY26 revenue growth to 2%-3% from 4%-5%, slashes NPATA growth to 4%-7% from 7%-10%

** Jarden says flu revenue impact for current Northern Hemisphere season "far worse than anticipated", with outlook downgrade so early in FY26 not helping sentiment

** CSL down 36.2% YTD

 (Reporting by Shivangi Lahiri and Nikita Maria Jino in Bengaluru)

 ((shivangi.lahiri@thomsonreuters.com))